(0.37%) 5 258.50 points
(0.30%) 39 654 points
(0.44%) 18 294 points
(0.40%) $79.58
(0.43%) $2.31
(1.71%) $2 380.30
(2.12%) $28.97
(1.26%) $1 003.30
(0.00%) $0.927
(-0.47%) $10.81
(-0.09%) $0.798
(-0.30%) $92.26
-0.03% $ 67.52
@ $82.68
Emitido: 14 feb 2024 @ 09:30
Retorno: -18.33%
Señal anterior: feb 12 - 12:22
Señal anterior:
Retorno: -0.71 %
Live Chart Being Loaded With Signals
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial...
Stats | |
---|---|
Volumen de hoy | 306 532 |
Volumen promedio | 486 387 |
Capitalización de mercado | 4.36B |
EPS | $0 ( 2024-05-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -31.12 |
ATR14 | $0.0620 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-06 | Shair Matthew | Sell | 29 600 | Class A Common Stock |
2024-05-06 | Shair Matthew | Sell | 7 900 | Class A Common Stock |
2024-05-02 | Miller Deborah Ann | Sell | 3 000 | Stock Option (Right to Buy) |
2024-05-02 | Miller Deborah Ann | Buy | 3 000 | Class A Common Stock |
2024-05-02 | Miller Deborah Ann | Sell | 1 566 | Class A Common Stock |
INSIDER POWER |
---|
-39.41 |
Last 100 transactions |
Buy: 779 479 | Sell: 1 638 582 |
Volumen Correlación
Nuvalent, Inc. Correlación
10 Correlaciones Más Positivas | |
---|---|
HURC | 0.845 |
BIMI | 0.84 |
CRBU | 0.837 |
AMRS | 0.836 |
GRPN | 0.833 |
SPRB | 0.832 |
WRAP | 0.827 |
ASUR | 0.821 |
LMST | 0.819 |
CHB | 0.818 |
10 Correlaciones Más Negativas | |
---|---|
PAAS | -0.871 |
RING | -0.859 |
EH | -0.854 |
HSON | -0.837 |
SABRP | -0.832 |
AMRK | -0.826 |
ALR | -0.822 |
DYAI | -0.82 |
LWAY | -0.812 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nuvalent, Inc. Correlación - Moneda/Commodity
Nuvalent, Inc. Finanzas
Annual | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-2.17 |
FY | 2023 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-2.17 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-1.480 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-2.87 |
Financial Reports:
No articles found.
Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico